Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096570 | 0.94 | PTGDR (0.42) | PTGDRPTGDR2PPARDPPARADDR1 | |
| SCHEMBL12096575 | 0.94 | PTGDR (0.42) | PTGDRPTGDR2PPARDPPARADDR1 | |
| SCHEMBL12096613 | 0.94 | PTGDR (0.42) | PTGDRPTGDR2PPARDPPARADDR1 | |
| SCHEMBL12096590 | 0.90 | PTGDR (0.41) | PTGDRPTGDR2PPARDPPARADDR1 | |
| SCHEMBL12096600 | 0.90 | PTGDR (0.41) | PTGDRPTGDR2PPARDPPARADDR1 | |
| SCHEMBL2638919 | 0.90 | TRPV1 (0.43) | PTGDRPTGDR2DDR1SIGMAR1HRH1 | |
| SCHEMBL12096585 | 0.89 | KCNK2 (0.40) | PTGDRPTGDR2PPARDPPARADDR1 | |
| SCHEMBL12096635 | 0.88 | PTGDR (0.38) | PTGDRPTGDR2PPARDPPARADDR1 | |
| SCHEMBL1548431 | 0.86 | MRGPRX4 (0.45) | PTGDRPTGDR2PPARDPPARADDR1 | |
| SCHEMBL15196455 | 0.85 | ALDH1A1 (0.35) | MRGPRX4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373162-B1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NOVARTIS AG (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-8168681-B2 | Amidoacetonitrile compounds and pesticidal composition thereof | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20110230563-A1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230563-A1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NAAA, PTMS, NIT2 | PTGDR 3120/4885PTGDR2 3228/4885PPARD 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.